Navigation Links
Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
Date:4/10/2008

NEW YORK, April 10 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (AMEX: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA") for its MedicRead Colon workstation. Medicsight will launch this workstation via a Chinese dealer network which gives the Company access to almost 1000 sales representatives.

David Sumner, Chief Executive of Medicsight, commented: "This is another significant milestone for Medicsight and we are delighted to have received approval from the SFDA. China is one of the world's fastest growing medical imaging markets and is one of Medicsight's core target markets, with a high installed base of MDCT (Multidetector Computed Tomography), high incidence of colorectal cancer and a large population. In anticipation of this approval, Medicsight has been working closely with its Chinese dealer network in preparation for the national launch in Guangzhou during the May Chinese Society of Abdominal Radiology congress."

President Qi Ji, President of the Chinese Society of Radiology, said, "We have been working with Medicsight for three years as part of their Chinese clinical program. We have been delighted with the performance of Medicsight's products, which have proven to make a marked difference in the speed and accuracy of our diagnosis. As the number of patients in China increases, CAD software is becoming increasingly important for radiologists where improved workflow and productivity support their efforts to save lives. I am delighted that Medicsight's products will now be available to radiologists across China."

MedicRead Colon is an advanced visualization workstation for CT Colonography and combines Medicsight's ColonCAD computer-aided detection technology with 3D imaging tools to assist radiologists in the detection of colorectal neoplasia (polyps). This software reduces the workload of radiologists by automatically highlighting suspicious areas on scan images, and may also help radiologists detect possibly malignant tumors at an early stage when treatment is most likely to be successful.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a leading developer of computer-aided detection (CAD) software solutions. Medicsight's CAD solutions help clinicians utilizing Computed Tomography (CT) scans to identify, measure and analyze suspicious pathology within the colon and lungs. The Medicsight CAD products are validated against one of the world's largest databases of verified CT scan data collected from leading healthcare institutions from around the world. Medicsight products allow radiologists and physicians to review scans more quickly and accurately -- saving both time and lives.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight Announces New Marketing Partnership with INFINITT
2. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
3. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
4. ATS Medical Announces First North American Commercial Implant of the ATS 3f Aortic Bioprosthesis
5. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
6. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
7. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
8. Oncothyreon announces effectiveness of shelf registration statement
9. Novagali Pharma Announces the Launch of Cationorm(R)
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. Dendreon Announces Closing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- NxGen MDx announced today that it brought its NxGen Informed Prenatal ... able to improve customer service through shortened turnaround times and at the ... CEO of NxGen MDx. ... A decrease in turnaround times by 25% ... opportunities at the Grand Rapid headquarters. The NxGen Informed Prenatal ...
(Date:12/5/2016)... 2016 The U.S. Biotechnology industry ... billion of revenue and some $890 billion of total ... global biopharmaceuticals, and this figure is expected to exceed ... up these four equities for assessment: Northwest Biotherapeutics Inc. ... ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016  In five ... of Hematology (ASH) Annual Meeting and Exposition in ... biomedical engineering methods to improve the delivery of life-saving ... These new methods are designed to carry therapies directly ... needed most, which could provide a substantial advantage over ...
(Date:12/2/2016)... 2016 More than $4.3 million was raised last ... DHMD ). The gala was held at the American Museum ... and honored Alan Alda and ... and medicine and the public understanding of science. Since the ... event has raised $40 million for the Laboratory,s research and ...
Breaking Biology Technology:
(Date:11/24/2016)... 23, 2016 Cercacor today introduced Ember TM ... trainers non-invasively measure hemoglobin, Oxygen Content, Oxygen ... Respiration Rate in approximately 30 seconds. Smaller than a ... immediate access to key data about their bodies to ... regimen. Hemoglobin carries oxygen to muscles. ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
Breaking Biology News(10 mins):